600223 Lushang Freda Pharmaceutical
- 8.74
- -0.05-0.57%
Lushang Freda Pharmaceutical News
Freda (600223): Cosmetics Q1 growth rate is steady, real estate returns are abundant and cash is expected to help growth
Key investment events: The large fluctuation in 24Q1 performance is within expectations. Payments related to the real estate divestment have been made, cash on the books is abundant, and the balance and liability structure has been optimized. 24Q1: Revenue of 891 million (-30%, year-on-year in parentheses, same below)
A Piece Of The Puzzle Missing From Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) Share Price
It's not a stretch to say that Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) price-to-earnings (or "P/E") ratio of 34.4x right now seems quite "middle-of-the-road" compared to the market in C
Freda (600223): Steady growth of cosmetics deducts sharp increase in net profit from non-return to mother
Looking back on the incident, the company released its report for the first quarter of '24. During the reporting period, the company achieved revenue of 890 million yuan, a year-on-year decrease of 30.0%, realized net profit of 60 million yuan to mother, a decrease of 54.4%, and realized net profit of 50 million yuan after deducting non-return to mother
Freda (600223): Net profit deducted from non-return mother in 24Q1, YOY +242.5%, cosmetics, steady bottom in the first quarter, optimistic about the company's successful state-owned enterprise reform
Incident: The company released its 2024 quarterly report, achieving revenue of 890 million yuan, yoy -30%, net profit to mother of 59 million yuan, yoy -54.4%, net profit deducted from non-return mother of 52 million yuan, yoy+242.
Freda (600223): Steady revenue growth deducts good non-profit performance
Core view: Incident: The company released a quarterly report. In 24Q1, it achieved revenue of 890 million yuan, -30.0% year on year; net profit to mother of 60 million yuan, or -54.4% year on year; net profit after deducting non-return to mother of 50 million yuan, +2 year on year
Freda (600223): Rapid balance and liability optimization, cosmetics profit margins have increased
Core view 24Q1 cosmetics business revenue was 544 million yuan, +15.14% year over year, including Yilian 200 million yuan, +17.45%, Dr. Eyre 294 million yuan, +20.63%. The company focused on the two major brands
Freda (600223): Steady development of the cosmetics business and continuous optimization of profit levels
The company's first-quarter results showed significant changes due to the divestment of the real estate business. The company achieved revenue of 891 million yuan/yoy -29.99% in 2024Q1, net profit of 59 million yuan/yoy -54.35%, deducted
Freda (600223) 2024 Quarterly Report Review: A sharp increase in non-net profit deductions can be expected, and efficiency improvements in the health industry can be expected
Key Investment Points 2024Q1 Net profit increased after deducting non-return to mother. 2024Q1 achieved revenue of 891 million yuan (YoY -29.99%, same below), net profit to mother of 59 million yuan (-54.4%), net of net income not attributable to mother
Freda (600223): The cosmetics business continues to grow, the raw materials business is steady, and the layout of the health landscape can be expected in the future
Incident: Freda publishes its 2024 quarterly report. In 24Q1, the company achieved revenue of 891 million yuan, -29.99%; net profit attributable to mother of 59 million yuan, or -54.35% year-on-year; net profit after deducting 0.52 million yuan
Freda (600223): Looking forward to an acceleration in the company's performance growth in the future
The 24Q1 cosmetics business maintained steady growth. 24Q1's revenue was 891 million yuan/yoy -29.99%, and net profit was 59 million yuan/yoy -54.35%, mainly due to the divestment of the real estate business in the same period last year
Freda (600223.SH) announced first-quarter results, net profit of 59.04 million yuan, a year-on-year decrease of 54.35%
Freda (600223.SH) disclosed its report for the first quarter of 2024. The company achieved revenue of 8.91 during the reporting period...
Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) Market Cap Dropped CN¥539m Last Week; Private Companies Bore the Brunt
Key Insights Significant control over Lushang Freda PharmaceuticalLtd by private companies implies that the general public has more power to influence management and governance-related decisions 53%
Freda (600223): Cosmetics are growing at an accelerated pace, and healthy growth can be expected
Focusing on Big Health and Light Equipment, the compound growth rate of Big Health's performance in 19-23 was 27%. The company's predecessor, Lushang Development, began entering the health sector by acquiring 100% of Shandong Freda Pharmaceutical Group's shares in 18 years, and started the real estate industry in November '22
Concerns Surrounding Lushang Freda PharmaceuticalLtd's (SHSE:600223) Performance
Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) healthy profit numbers didn't contain any surprises for investors. We think this is due to investors looking beyond the statutory profits and bei
Freda (600223): Successfully completed the transformation, and the cosmetics business continues to accelerate
The incident describes the company's release of the 2023 annual report. The company achieved operating income of 4.579 billion yuan, a year-on-year decrease of 65%, achieved net profit of 303 million yuan, a year-on-year increase of 567%, and achieved net profit of 139 million yuan after deduction of non-return to mother
Freda (600223) Annual Report Review Report: Performance exceeds the forecast limit, the two-US strategy is expected to drive high-quality growth
Financial indicators fluctuated greatly due to the divestment of real estate, and net profit attributable to the mother exceeded the forecast limit. The company achieved revenue of 4.579 billion yuan (yoy -64.65%) in 2023, mainly due to the divestment of the real estate business, with a net profit of 3.03 billion yuan to the mother
Freda (600223): Cosmetics revenue in '23 YOY +22.2% real estate divestment to achieve company transformation and is optimistic about the company's steady future development
Incident: The company released its 2023 annual report, with annual revenue of 4.579 billion yuan, yoy -64.65%, mainly due to the divestment of the real estate business; net profit to mother was 305 million yuan, yoy +567.44%, and the performance side was higher than before
Freda (600223): Cosmetics are on the right track and development is expected to accelerate in the first year of transformation
Key investment events: The real estate business disrupts apparent performance. It is expected that after deducting the impact of real estate, the performance is basically in line with expectations. Year 23: Revenue of $4.58 billion (-65%, YoY in parentheses, same below), net profit to mother of $30 billion (+56)
Freda (600223) 2023 performance review: The performance exceeds the forecast upper limit, and we expect 24 young people to go to battle and be fully healthy
Incident: The company recently announced its 2023 annual report, with 2023 revenue of 4.58 billion yuan/-65%, net profit to mother of 305 million yuan/same +567%, net profit of non-return to mother of 139 million yuan/same +137
Freda (600223): Successful transformation and lightweight cosmetics have strong potential
Incident: Freda released its 2023 annual report. In 2023, the company achieved revenue of 4.579 billion yuan/ -64.65%, net profit to mother of 303 million yuan/ +567.44%, after deducting non-return net profit of 139 million yuan
Analysis
Price Target
No Data
